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Pi-Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), SpainChronic liver diseases are amongst the top leading causes of tance due to moderate splanchnic arterial vasodilation which is
death in Europe as well as in other areas of the world [1–3].
Chronic liver diseases are characterized by unrelenting progres-
sion of liver inﬂammation and ﬁbrosis over a prolonged period
of time, usually more than 20 years, which may eventually lead
to cirrhosis [4]. Advanced cirrhosis leads to a complex syndrome
of chronic liver failure which involves many different organs
besides the liver, including the brain, heart and systemic circula-
tion, adrenal glands, lungs, and kidneys [5]. The high morbidity
and mortality secondary to chronic liver failure is due to compli-
cations related to the dysfunction of these organs, either alone or,
more frequently, in combination. Understanding the mechanisms
leading to organ dysfunction is crucial to the development of
strategies for treatment and prevention of complications of cir-
rhosis. This article reviews our current knowledge, as well as
future perspectives, on the management of circulatory and renal
dysfunction in chronic liver failure.
 2010 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
A brief review of the current understanding of renal and
circulatory dysfunction in cirrhosis
Awealth of evidence indicates that impairment in circulatory func-
tion is themain causeof renal dysfunction in cirrhosis. Thedysfunc-
tion in the systemic arterial circulation is largely characterized by a
reduction in systemic vascular resistance due to primary arterial
vasodilationof the splanchnic circulation triggeredbyportal hyper-
tension [6–9]. The relationship between liver disease, portal hyper-
tension, and abnormalities in splanchnic circulation is discussed in
detail in several recent reviews [4,10,11]. The vasodilation of the
splanchnic arterial circulation is due to an increased production/
activity of vasodilator factors, particularlynitric oxide, carbonmon-
oxide, and endogenous cannabinoids [7–13].
At the early stages of cirrhosis, when patients are usually
asymptomatic and with normal physical status, the increase in
hepatic vascular resistance, mainly due to ﬁbrosis, is moderate
and therefore the increase in portal pressure is also moderate. In
this context, there is a slight reduction in systemic vascular resis-Journal of Hepatology 20
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E-mail address: pgines@clinic.ub.es (P. Ginès).compensated by an increase in cardiac output, thus permitting
arterial pressure and effective arterial blood volume to remain
within normal limits [6,7]. In advanced stages of cirrhosis, when
patients are usually symptomatic and have already developed
some complications of the disease, the reduction in systemic vas-
cular resistance is marked and cannot be compensated by further
increases in cardiac output; therefore, underﬁlling of the arterial
circulation develops, there being a disarrangement between the
intravascular blood volume and a very enlarged intravascular
arterial circulation [7]. Moreover, evidence indicates that at this
stage of the disease there is a reduction in the cardiac output that
contributes to the arterial underﬁlling [14]. In this context of
marked underﬁlling of the arterial circulation, arterial pressure
must be maintained by the activation of vasoconstrictor systems,
including the renin–angiotensin-system, the sympathetic nervous
system, and, at late stages, a non-osmotic hypersecretion of argi-
nine vasopressin (the antidiuretic hormone) [7]. These systems
help maintain effective arterial blood volume and arterial pres-
sure but have important effects on kidney function, particularly
sodium and solute-free water retention with accumulation of
ascites and edema. If the activation of these systems is extreme,
renal vasoconstriction leading to markedly reduced glomerular
ﬁltration rate may occur, a condition known as hepatorenal syn-
drome (HRS) [7,8]. Other factors that may contribute to the devel-
opment of HRS are vasoactive mediators acting on the intrarenal
circulation. An increased synthesis of several vasoactive factors
in the intrarenal circulation, which may affect renal blood ﬂow
or glomerular ﬁltration rate, such as cysteinyl leukotrienes,
thromboxane A2, F2-isoprostanes, and endothelin-1, has been
reported, yet the role of these factors in the pathogenesis of HRS
remains poorly understood [6]. Nonetheless, a role for endothe-
lin-1 is unlikely since the administration of the endothelin antag-
onist tazosentan does not improve renal function in patients with
type 2 HRS [15]. Recent data indicate that impairment in the car-
diac function, likely due to cirrhotic cardiomyopathy, is a risk fac-
tor for the development of HRS and likely further contributes to
the impairment of the arterial blood volume that is related to
splanchnic vasodilation [16,17]. A summary of the pathogenesis
of ascites and functional renal abnormalities with possible thera-
peutic interventions are shown in Figs. 1–3.
Awealth of evidence indicates that altered splanchnic hemody-
namics is related to the development of portal hypertension [11].
On the other hand, studies in both experimental animals and
patients with cirrhosis suggest that bacterial translocation, the10 vol. 53 j 1135–1145
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Fig. 1. Schematic representation of the proposed pathogenesis of ascites and edema formation in cirrhosis. Established therapies are given on the left side and
potential new therapies on the right. TIPS, transjugular intrahepatic portosystemic shunt.
Reviewpassage of bacteria from the intestinal lumen tomesenteric lymph
nodes, may play an important role in circulatory dysfunction in
advanced cirrhosis [18,19]. Bacterial translocation may elicit an
inﬂammatory response with increased production of proinﬂam-
matory cytokines in the splanchnic area, which may in turn lead
to vasodilatation of the splanchnic arterial vessels. Patients with
cirrhosis and increased levels of lipopolysaccharide-binding pro-
tein or circulating levels of bacterial DNA, which are considered
surrogate markers of bacterial translocation, have higher serum
levels of cytokines, lower systemic vascular resistance, and higher
cardiac output when compared to those who do not [20,21]. The
important role of bacterial translocation in circulatory dysfunction
is further supported by the observation that the administration of
norﬂoxacin, an antibiotic that causes selective intestinal decon-
tamination, improves circulatory function [22,23].The expanded extracellular ﬂuid volume: ascites and edema
Sodium is the main determinant of the volume of the extracellu-
lar ﬂuid (ECF). In healthy subjects the amount of sodium is main-
tained constant through a very precise equilibrium between
sodium intake and sodium excretion by the kidneys [24,25]. In
advanced cirrhosis, this equilibrium is lost because of an
increased retention of sodium in the kidneys and positive sodium1136 Journal of Hepatology 2010balance develops leading to expansion of the ECF [26,27]. The
excess of ECF is mainly stored in the peritoneal cavity (because
of the high pressure of the splanchnic capillaries due to portal
hypertension) and in the interstitial tissue of the legs (because
of the high pressure of the capillaries of the lower extremities),
causing ascites and edema, respectively. Excessive ECF may also
be stored in other locations, such as the pleural space, causing
pleural effusion. Ascites and edema are the most frequent com-
plication of patients with advanced chronic liver diseases.
Current management
The current management of ascites and edema is based on die-
tary salt restriction together with diuretics to increase renal
sodium excretion [28] (Table 1). The aim of the treatment is
therefore to achieve a natriuresis higher than sodium intake that
causes negative sodium and ﬂuid balance with weight loss and
reduction in the ECF volume. The diuretics of choice are aldoste-
rone antagonists, because of the increased aldosterone secretion
present in cirrhosis [29]. Administration of loop diuretics (mainly
furosemide) in combination with aldosterone antagonists may be
helpful in patients with recurrent ascites [28]. Diuretic treatment
is effective in more than two thirds of patients with ascites. Doses
of diuretics should be adjusted according to several factors, par-
ticularly whether the episode of ascites is the ﬁrst or recurrent,vol. 53 j 1135–1145
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JOURNAL OF HEPATOLOGYseverity of sodium retention, presence of renal impairment, and
electrolyte abnormalities. The management of ascites and edema
with diuretics is not simple and requires a great deal of experi-
ence to achieve a high efﬁcacy and at the same time minimizing
the risk of diuretic-induced complications. Several guidelines for
diuretic use have been reported recently [28,30–32]. There are
two main drawbacks of diuretic therapy for ascites: the lack of
efﬁcacy in approximately 10–20% of patients and the develop-
ment of complications, particularly hepatic encephalopathy,
renal impairment, and electrolyte disturbances, which have been
reported in up to 40% of patients. Therefore, there is a clear need
for improving our current therapy of ascites.Journal of Hepatology 2010The problems with diuretic therapy gave rise to another
approach for management of ascites which is large-volume par-
acentesis (LVP, i.e. removal of large amounts of ascitic ﬂuid)
[33]. LVP is very effective and is the treatment of choice for both
patients with large ascites and those with recurrent ascites due
to lack of response to diuretics (i.e. refractory ascites) [28,30–
32]. LVP requires the associated administration of albumin to
prevent an impairment of circulatory function that may occur
with the removal of large amounts of ascitic ﬂuid [34]. The main
disadvantages of LVP are that it is time consuming, involves the
administration of albumin, which is not easily available in all
settings, and does not prevent the recurrence of ascites because
it does not interfere with the main mechanisms of ascites for-
mation. An alternative approach to treatment with LVP and
albumin for patients with an unresponsive ascites (refractory
ascites) is the use of transjugular intrahepatic portosystemic
shunts (TIPS). TIPS consist of an autoexpandable stent inserted
through a transjugular approach which causes a remarkable
reduction in portal pressure and decreases renal sodium reten-
tion. Although effective in the management of ascites, the use
of TIPS has signiﬁcant disadvantages over LVP plus albumin,
including its limited applicability (it cannot be used in patients
with severe liver failure or recurrent hepatic encephalopathy),
high cost, increased risk of hepatic encephalopathy, and need
of expertise for its insertion [35–38]. On this basis, TIPS is con-
yponatremia in cirrhosis. Established therapies are given on the left side and
rvolemic hyponatremia in cirrhosis in United States and Japan, but not in Europe.vol. 53 j 1135–1145 1137
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Fig. 3. Schematic representation of the proposed pathogenesis of hepatorenal syndrome in cirrhosis. Established therapies are given on the left side and potential new
therapies on the right. *The use of TIPS, transjugular intrahepatic portosystemic shunt, has been reported in some studies but the information is very limited.
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Reviewsidered a second-line therapy for refractory ascites in all recent
guidelines [28,30–32].
Besides their efﬁcacy in preventing variceal bleeding, non-
selective ß-blockers could have beneﬁcial effects on the pre-
vention of other complications of cirrhosis by reducing portal
pressure, including development of ascites. Patients demonstrat-
ing a positive response to ß-blockers, that is characterized by
marked reduction in hepatic venous pressure gradient, afterwards
show a decreased risk of ascites development during follow-up
compared to patients who display no response [39,40]. In
apparent contradictionwith these ﬁndings, a recent study showed
that in patients with refractory ascites, treatment with ß-blockers
was an independent risk factor for mortality, suggesting that
these drugs may have deleterious effects in patients with
advanced cirrhosis [41]. The results of this study indicate that
the issue of beneﬁt vs. risk of treatment with ß-blockers in
patients with cirrhosis deserves an extensive investigation.
Future therapeutic options
The ideal therapeutic approach to management of ascites and
edema in cirrhosis would consist of a drug able to reverse the cir-
culatory dysfunction present in cirrhosis (which would suppress1138 Journal of Hepatology 2010the mechanisms responsible for sodium retention) with or with-
out combination with diuretics to enhance the excretion of the
sodium retained together with the ﬂuid. Although this ideal drug
does not exist at present, several methods to improve the man-
agement of ascites have been attempted or are currently under
investigation (Table 1).
Two different approaches have been investigated using drugs
that interact with the activity of the sympathetic nervous system.
In the ﬁrst approach, the administration of clonidine, a drug that
causes a suppression of the sympathetic nervous outﬂow from
the central nervous system, in patients with cirrhosis and ascites
was associated with lower ascites recurrence and reduced need
for diuretic administration compared to a control group of
patients receiving standard therapy without clonidine [42]. The
beneﬁcial effects of this approach are probably related to sup-
pression of the afferent sympathetic activity to the renal nerves
which has been shown to participate in renal sodium retention
[43,44]. In a second approach, that appears contradictory with
the previous one, the administration of midodrine, an orally
active a-adrenergic agonist, in patients with cirrhosis and ascites
improved circulatory function, as indicated by an increase in
arterial pressure and suppression of the activity of the renin–
angiotensin and sympathetic nervous systems [45,46]. Thisvol. 53 j 1135–1145
Table 1. Treatment of ascites: current management and potential future options.
*TIPS, transjugular intrahepatic portosystemic shunt.
JOURNAL OF HEPATOLOGYimprovement in circulatory function was associated with
increases in renal plasma ﬂow, glomerular ﬁltration rate, and uri-
nary sodium excretion. However, in these studies, midodrine was
given for a short period of time and its potentially beneﬁcial
effects in the management of ascites and edema have not yet
been assessed. No signiﬁcant side effects were reported in these
two short-term studies, but the long-term safety is unknown. It
would be worthwhile to perform studies in a large series of
patients to assess the usefulness of both approaches in the
long-term management of ascites.
The administration of albumin has potentially beneﬁcial
effects on circulatory function in patients with cirrhosis [47].
Moreover, a prospective study in patients with cirrhosis and asci-
tes showed that the long-term administration of albumin
increased survival compared to a control group of patients not
receiving albumin [48]. Nevertheless, the usefulness of this
approach requires validation in other studies before it becomes
a standard of treatment for patients with cirrhosis. An interesting
approach to improve circulatory and renal function in cirrhosis is
to combine the administration of albumin together with cloni-
dine or midodrine. This approach is currently being tested in
patients in the waiting list for liver transplantation
(www.clinicaltrials.gov).
In contrast to these approaches that show promising results,
there have been a number of other approaches that have failed
in recent years. An increased production of the vasodilator factor
nitric oxide likely plays a major role in the development and
maintenance of splanchnic arterial vasodilation in cirrhosis
[9,49]. Moreover, in experimental cirrhosis the normalization of
the overproduction of nitric oxide is associated with an improve-
ment of renal and circulatory function and reduction/disappear-
ance of ascites [50]. Unfortunately, the inhibitors of the nitric
oxide system were withdrawn from development because of
important side effects in patients with septic shock [51].
In contrast to the splanchnic and systemic circulation in
which there is overproduction of nitric oxide, in the intrahepatic
circulation the production of nitric oxide is markedly decreased,
which may be a factor contributing to an increased intrahepatic
vascular resistance and portal hypertension [10,52]. Therefore,
the hypothesis was raised that increasing NO in the intrahepatic
circulation could have beneﬁcial effects in portal pressure.
Attempts to decrease portal hypertension by the selective deliv-Journal of Hepatology 2010ery of nitric oxide to the liver were promising in experimental
portal hypertension but have so far failed in human cirrhosis
[53,54].
Recent studies in experimental animals with cirrhosis suggest
that the endocannabinoid system plays a role in the splanchnic
vasodilation of cirrhosis and that inhibition of the endocannabi-
noid system with the use of CB1 endocannabinoid antagonists
improves renal function and sodium excretion in experimental
cirrhosis [55–57]. Unfortunately, rimonabant, a drug that antag-
onizes both central and peripheral CB1 receptors, was recently
withdrawn from the market in Europe (the drug was not
approved in the USA) due to an increased risk of depression in
patients treated for obesity. This approach to management of
ascites will have to be re-explored if selective antagonists of
the peripheral CB1 receptors become available.
A ﬁnal approach that has been tested in recent years is
whether the combination of diuretics with satavaptan, a drug
that selectively antagonizes the renal V2 receptors of vasopressin,
the antidiuretic hormone, could improve the management of
ascites [58]. In phase 2 studies, the combination of satavaptan
with diuretics for a short period of time was associated with a
decrease in ascites volume and reduced the need for large-vol-
ume paracentesis in patients with difﬁcult-to-treat ascites [59–
61]. Nevertheless, phase 3 double-blind studies showed that
when this combination was used for prolonged periods of time,
the effectiveness in the control of ascites was very limited and
treatment was associated with an increased mortality compared
to a control group of patients receiving placebo plus standard
therapy with diuretics alone [62,63]. The reason for this increased
risk of death in patients receiving satavaptan in combination with
diuretics for the long-term treatment of ascites is currently
unknown.The disturbed renal water homeostasis: hypervolemic
hyponatremia
Hypervolemic hyponatremia is a frequent complication of patients
with advanced cirrhosis that consists of a decreased serum sodium
concentration in the setting of an expanded extracellular ﬂuid
volume with ascites and edema [64]. It is generally accepted that
the main pathogenic factor of hypervolemic hyponatremia is anvol. 53 j 1135–1145 1139
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impairment of renal solute-free water excretion secondary to an
excessive production of vasopressin stimulated by circulatory
dysfunction, yet other factors may also participate [64]. Some
patients develop hypervolemic hyponatremia in the setting of a
preserved renal capacity to eliminate solute-free water [65]. The
pathogenesis of this latter disorder is unknown and deserves
investigation. The interest in hypervolemic hyponatremia has
been fostered by the observation that hyponatremia is a risk factor
of hepatic encephalopathy and death [66–71].
Hypervolemic hyponatremia should be differentiated from
hypovolemic hyponatremia, a less common condition character-
ized by low sodium levels in the setting of contraction of the
extracellular ﬂuid volume and plasma volume due to marked
and prolonged loss of sodium. This condition is managed by with-
drawing the cause of sodium loss (usually diuretics) and admin-
istration of saline solutions and will not be discussed further in
this review.Current management
For many years there has been no effective pharmacological ther-
apy for the management of hypervolemic hyponatremia. Several
drugs, including demeclocycline and j-opioid agonists, were
found to increase serum sodium concentration in pilot studies,
but were abandoned due to side effects [72,73]. Because of the
absence of effective drugs, treatment has relied on ﬂuid restric-
tion (to approximately 1 L/day) with the aim of causing a nega-
tive ﬂuid balance. However, since urine volume is low in these
patients, a negative ﬂuid balance is infrequently achieved. This
is the reason why ﬂuid restriction is seldom effective in increas-
ing serum sodium concentration in these patients. Hypertonic
saline has been used but it is usually not effective and markedly
increases ascites and edema due to the intense sodium retention
present in these patients. Therefore, its use is not currently rec-
ommended [28].
In recent years, a new generation of drugs, known as vaptans,
which selectively antagonize the vasopressin V2 receptors pres-
ent in the renal tubules, has come into play [58]. Some of these
drugs are currently licensed for hyponatremia associated with
high vasopressin levels. In the US, conivaptan (a dual V1/V2
antagonist) was approved few years ago for short-term (5 days)
intravenous use. More recently, tolvaptan (a selective oral V2
antagonist) was approved by the FDA for severe hyponatremia
(<125 mmol/L) associated with cirrhosis, cardiac failure, and the
syndrome of inappropriate antidiuretic hormone secretion
(SIADH). In Europe, conivaptan is not available and tolvaptan is
approved only for SIADH. There is very little information on coni-
vaptan use in patients with cirrhosis [74]. In randomized studies,
the administration of tolvaptan to patients with cirrhosis and
hypervolemic hyponatremia induced a marked increase in urine
volume and solute-free water excretion and a signiﬁcant increase
(normalization in some patients) in serum sodium levels [75,76].
Reversal of hyponatremia was associated with an improvement
of the mental component of a quality of life score, suggesting a
beneﬁcial effect of the enhanced serum sodium levels on cerebral
function. No adverse effects were noticed in these studies, except
for thirst and a remarkable increase in urine volume in some
patients. Unfortunately, however, the duration of tolvaptan ther-
apy in these studies was of only one month. The Clinical Practice
Guidelines of the European Association for the Study of the Liver
(EASL) recommend tolvaptan for short-term management of1140 Journal of Hepatology 2010patients with severe hypervolemic hyponatremia (<125 mmol/L)
[28]. Treatment should be initiated in the hospital at low doses
(15 mg/day) with frequent monitoring of serum sodium to avoid
a rapid increase in serum sodium concentration (<8–10 mmol/
day) and the dose increased stepwise until a normalization of
serum sodium levels has been achieved. Neither ﬂuid restriction
nor hypertonic saline should be used concomitantly with tolvap-
tan to avoid a too rapid increase in serum sodium concentration.
Treatment may be particularly useful in patients with hyponatre-
mia who have to undergo surgery, particularly liver transplanta-
tion, to reduce the increased risk of complications after
transplantation in patients with hyponatremia [77]. It is likely
that the improvement/normalization of serum sodium concen-
tration may reduce the risk of severe neurological complications
in these patients, particularly central pontine myelinolysis. None-
theless, more information is needed on the use of vaptans in the
management of hypervolemic hyponatremia in cirrhosis, particu-
larly with respect to its long-term safety. This is important
because, as mentioned before, the development of one of these
drugs, satavaptan, was stopped because of the ﬁnding of
increased frequency of complications and reduced survival com-
pared to placebo in a phase 3 study assessing the efﬁcacy of this
drug in the management of ascites in patients with cirrhosis [63].
Future therapeutic options
The future of management of hypervolemic hyponatremia in cir-
rhosis is likely linked to the use of vaptans. However, there are
several aspects of the use of vaptans that are worth of comment.
First, the cautious use of vaptans cannot be overemphasized.
Treatment should be started in the hospital and patients moni-
tored closely during the treatment, and serum sodium levels
measured at regular intervals, particularly at the beginning of
the treatment, when the dose is increased or whenever there is
a change in the clinical status of patients. Second, there is increas-
ing evidence that patients with hyponatremia represent a heter-
ogeneous population; therefore, it is of major importance to
understand which patients are to beneﬁt from treatment with
vaptans. Finally, there is a need for data on long-term safety
and efﬁcacy of treatment with vaptans in patients with cirrhosis
and hypervolemic hyponatremia. Another approach, besides vap-
tans, that would be of interest for the future, is the administration
of albumin since some studies have shown that repeated albumin
administration improves serum sodium concentration in patients
with cirrhosis and severe hyponatremia [78,79].The fascinating concept of functional renal vasoconstriction:
hepatorenal syndrome
Hepatorenal syndrome (HRS) is a unique form of renal failure
that develops in patients with cirrhosis, in the absence of signif-
icant histological abnormalities in the kidneys [80]. Until recent
years, the only therapeutic method capable of reversing HRS
was liver transplantation. Currently, reversal of HRS is achieved
with treatment with vasoconstrictor drugs associated with albu-
min [81–83]. As mentioned before, it is generally accepted that
HRS is of circulatory origin and occurs as a consequence of reduc-
tion in renal blood ﬂow and glomerular ﬁltration rate secondary
to marked arterial vasodilation in the splanchnic circulation. This
leads to a reduction in effective arterial blood volume and arterialvol. 53 j 1135–1145
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pressure with compensatory activation of vasoconstrictor sys-
tems, particularly sympathetic nervous system and renin–angio-
tensin–aldosterone system. An extended discussion of the
pathophysiology of HRS can be found elsewhere [81,84,85]. HRS
characteristically develops after a precipitating factor, particu-
larly a bacterial infection, most frequently spontaneous bacterial
peritonitis, although in some cases it may develop without an
identiﬁable precipitating factor. HRS occurs in two different
forms: type-1 HRS, characterized by rapidly progressive renal
failure usually in the setting of multiorgan failure, and type 2
HRS characterized by less severe and stable renal failure, which
is clinically apparent by ascites refractory to diuretic therapy.
The former is associated with a 1 month mortality rate greater
than 50%, whereas the latter shows a better survival [86].
Current management
The most effective method currently available for the manage-
ment of HRS is the administration of vasoconstrictor drugs
(Table 2). The vasoconstrictor of choice is the vasopressin ana-
logue terlipressin [28]. The rationale for the use of terlipressin
in HRS is to improve the markedly impaired circulatory function
by causing vasoconstriction of the extremely dilated splanchnic
vascular bed, increasing arterial pressure, and suppressing the
activity of the endogenous vasoconstrictor factors acting on the
kidney [87,88]. Terlipressin is effective in 40% to 50% of patients
with type-1 HRS [81,82,87]. Treatment is usually started at a dose
of 1 mg/4–6 h (iv bolus) and increased to a maximum of 2 mg/4–
6 h if there is no reduction in serum creatinine of at least 25%
compared to the baseline value at day 3 of therapy. Responder
patients usually show a progressive reduction in serum creati-
nine over several days and up to 1–2 weeks, together with an
increase in arterial pressure, urine volume, and serum sodium
concentration. Treatment is maintained until serum creatinine
decreases to 1–1.2 mg/dl (88–106 lmol/L). Predictive factors of
response are, pretreatment serum bilirubin levels lower than
10 mg/dl and an increase in mean arterial pressure greater than
5 mm Hg after 3 days of treatment [89]. Recurrence of HRS after
withdrawal of therapy occurs in less than 15% of patients and
retreatment with terlipressin is generally effective. The most fre-Table 2. Treatment of hepatorenal syndrome: current management and
potential future options.
*TIPS, transjugular intrahepatic portosystemic shunt.
Journal of Hepatology 2010quent side effects of treatment are cardiovascular or ischemic
complications, which have been reported in 12% of patients, yet
most studies excluded patients with known severe cardiovascu-
lar or ischemic conditions [81,87]. Terlipressin is given in combi-
nation with albumin (1 g/kg on day 1 followed by 40 g/day) to
improve the effect of treatment on circulatory function [90].
Whether terlipressin improves survival in patients with HRS is
not known, but a recent systematic review of randomized studies
using terlipressin as well as other vasoconstrictors showed an
increased short-term survival compared with control patients
[82]. The effectiveness of terlipressin in the treatment of HRS
with active bacterial infection is unknown, because all clinical tri-
als have excluded patients with ongoing infections. Finally, treat-
ment with terlipressin in patients with type 2 HRS is also
associated with an improvement of renal function [91,92]. Never-
theless, there is still limited information on the use of terlipressin
in type 2 HRS.
Vasoconstrictors other than terlipressin that have been used
in the management of type-1 HRS include noradrenaline and
midodrine (plus octreotide), both in combination with albumin.
Midodrine is given orally at doses starting from 2.5 to 75 mg/
8 h and octreoide 100 lg/8 h subcutaneously, with an increase
to 12.5 mg/8 h and 200 lg/8 h, respectively, if there is no
improvement in renal function [93,94]. Noradrenaline (0.5–
3 mg/h) is administered as a continuous infusion and the dose
increased to achieve a raise in arterial pressure [95]. Although
both vasoconstrictor drugs improve renal function, the number
of patients reported so far using these treatments is very small
and no randomized comparative studies have been performed
to evaluate its efﬁcacy compared with placebo.
Although TIPS may reverse HRS in some patients, the applica-
bility of TIPS in patients with type-1 HRS is low because TIPS is
contraindicated in patients with severe liver failure and hepatic
encephalopathy, which are common ﬁndings in the setting of
type-1 HRS [96]. Due to the paucity of data, more studies are
needed for assessing the use of TIPS in patients with HRS. Renal
replacement therapy (RRT) has been used in the management
of patients with type-1 HRS, especially in patient candidates for
liver transplantation, in an attempt to maintain patients alive
until liver transplantation is performed [97,98]. Although RRT is
not the ﬁrst line therapy, it is a temporary option in patients
not responding to vasoconstrictors or in those who develop
severe volume overload, metabolic acidosis and/or refractory
hyperkalemia. Most patients develop important side effects dur-
ing hemodialysis including severe arterial hypotension, bleeding,
and infections that may contribute to death during treatment.vol. 53 j 1135–1145 1141
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All patients with HRS should be considered for liver transplan-
tation, unless they have contraindications [99]. The main prob-
lems of liver transplantation for HRS are the high waiting list
mortality rate and an increased morbidity and mortality after
transplantation. Nevertheless, the survival of patients with HRS
treated with liver transplantation is approximately 60% at
3 years, a survival rate much higher than that expected by the
natural course of the disease.
There have been few studies on the prevention of HRS. The
administration of albumin (1.5 g/kg at diagnosis and 1 g/kg at
day 3) is effective in the prevention of HRS secondary to SBP
and has been shown to improve survival [100]. Short-term treat-
ment (4-week) with pentoxyfylline (400 mg three times a day)
was shown to prevent the development of HRS in patients with
severe alcoholic hepatitis [101]. In a more recent study, long-
term treatment with pentoxyfylline was associated with reduced
frequency of some complications of cirrhosis, including renal fail-
ure, yet this was not the primary end-point of the study [102].
More studies are needed to assess the usefulness of pentoxyfyl-
line in the prevention of HRS. Finally, long-term administration
of norﬂoxacin to patients with advanced cirrhosis (severe liver
failure with or without renal impairment or hyponatremia)
(400 mg/day) reduced the incidence of HRS and improved sur-
vival compared with placebo [103]. The potential mechanism(s)
by which pentoxyfylline and norﬂoxacin prevent HRS in cirrhosis
is/are not well understood, but may be related, at least in part, to
a reduction in cytokine levels that may have deleterious effects
on renal function.
Future therapeutic options
Approximately 50–60% of patients with HRS do not respond to
treatment with vasoconstrictors [89]. Therefore, one of the main
challenges for the future is to increase the number of patients
with HRS responding to pharmacological therapy. The ﬁrst step
in improving the efﬁcacy of pharmacological therapy is to under-
stand the pathogenic reasons for the lack of response. In this
regard, it would be important to perform studies in a large series
of patients with the aim of identifying predictive factors of
response. Possible approaches to improve the efﬁcacy of vasocon-
strictors include modiﬁcations in the method of administration of
the drugs and the combination of vasoconstrictors with other
therapies (Table 2). Preliminary results of an ongoing study sug-
gest that terlipressin is more effective when given as continuous
infusion than as iv bolus [104]. This might be to a lesser effect
related to the drug in impairing cardiac function in the former
compared to the latter method of administration [105]. A single
study in a very small series of patients suggests that treatment
with vasoconstrictors, followed by insertion of TIPS, is associated
with a marked improvement of renal function and prolonged sur-
vival [94]. This combined approach would require conﬁrmation
in a larger series of patients. An increased renal adenosine pro-
duction has been suggested to play a role in the pathogenesis
of HRS [106]. On this ground, the potential beneﬁt of antagoniz-
ing the effects of adenosine on renal function was investigated.
Unfortunately, the administration of an antagonist of A1 adeno-
sine receptors, increased natriuresis but did not improve glomer-
ular ﬁltration rate and no further studies have been published
investigating the use of adenosine receptors since 1998 [107].
Considering the potential relationship between impairment of
cardiac function and occurrence of HRS mentioned earlier in this
article [16], the possibility of treating HRS by improving cardiac1142 Journal of Hepatology 2010function should be investigated. Finally, two recent studies sug-
gest that the so called extracorporeal liver support systems
(either albumin dialysis using the molecular adsorbent recircu-
lating system -MARSR- and fractionated plasma separation and
adsorption -PrometheusR-) may be effective in the management
of HRS [108–110]. The beneﬁcial effects of such a therapy may
be related to the improvement in circulatory function related to
the elimination of vasodilator substances [111–113]. Studies spe-
ciﬁcally designed to address the efﬁcacy and safety of extracorpo-
real liver support systems in patients with HRS should be
performed to answer deﬁnitively the question of the potential
effectiveness of such therapies in HRS.Conﬂict of interests
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